-
Je něco špatně v tomto záznamu ?
New mutation in erythroid-specific delta-aminolevulinate synthase as the cause of X-linked sideroblastic anemia responsive to pyridoxine
J. Kucerova, M. Horvathova, R. Mojzikova, P. Belohlavkova, J. Cermak, V. Divoky,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NS10281
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
Medline Complete (EBSCOhost)
od 1998-01-01 do Před 1 rokem
PubMed
21252495
DOI
10.1159/000322870
Knihovny.cz E-zdroje
- MeSH
- 5-aminolevulátsynthetasa genetika metabolismus MeSH
- dospělí MeSH
- lidé MeSH
- mutace MeSH
- pyridoxin terapeutické užití MeSH
- sekvence nukleotidů MeSH
- sekvenční seřazení MeSH
- sideroblastická anemie farmakoterapie enzymologie genetika MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND/AIMS: Congenital sideroblastic anemias (SA) are characterized by the presence of ringed sideroblasts in the bone marrow. The most common form is X-linked SA, which results from mutations in erythroid-specific δ-aminolevulinate synthase (ALAS2), the first enzyme in heme biosynthesis. In addition, autosomal recessive mutations in the erythroid-specific mitochondrial transporter SLC25A38 and glutaredoxin 5 (GLRX5) have recently been identified in SA patients with isolated erythroid phenotype. MATERIALS AND METHODS: We studied 5 young males with congenital SA from the Czech Republic. Mutation analysis was performed on the complete coding regions of 3 candidate genes (ALAS2, SLC25A38 and GLRX5), and the enzyme activity of ALAS2 was measured by a continuous spectrophotometric assay. RESULTS: We found the previously published R452H and R452C ALAS2 mutations in 3 patients. A novel K156E substitution in ALAS2 was discovered in 1 pyridoxine-responsive patient. The functional study showed that this substitution severely decreases ALAS2 enzyme activity. In 1 pyridoxine-refractory patient, no mutations were detected in ALAS2, SLC25A38 or GLRX5. CONCLUSION: Our report extends the list of known ALAS2 mutations, with the addition of a novel K156E substitution that is responsive to pyridoxine treatment and contributes to the general knowledge of congenital SA cases characterized worldwide.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027863
- 003
- CZ-PrNML
- 005
- 20141211095641.0
- 007
- ta
- 008
- 120817e20110120sz f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1159/000322870 $2 doi
- 035 __
- $a (PubMed)21252495
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kucerova, Jana $u Department of Biology, Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
- 245 10
- $a New mutation in erythroid-specific delta-aminolevulinate synthase as the cause of X-linked sideroblastic anemia responsive to pyridoxine / $c J. Kucerova, M. Horvathova, R. Mojzikova, P. Belohlavkova, J. Cermak, V. Divoky,
- 520 9_
- $a BACKGROUND/AIMS: Congenital sideroblastic anemias (SA) are characterized by the presence of ringed sideroblasts in the bone marrow. The most common form is X-linked SA, which results from mutations in erythroid-specific δ-aminolevulinate synthase (ALAS2), the first enzyme in heme biosynthesis. In addition, autosomal recessive mutations in the erythroid-specific mitochondrial transporter SLC25A38 and glutaredoxin 5 (GLRX5) have recently been identified in SA patients with isolated erythroid phenotype. MATERIALS AND METHODS: We studied 5 young males with congenital SA from the Czech Republic. Mutation analysis was performed on the complete coding regions of 3 candidate genes (ALAS2, SLC25A38 and GLRX5), and the enzyme activity of ALAS2 was measured by a continuous spectrophotometric assay. RESULTS: We found the previously published R452H and R452C ALAS2 mutations in 3 patients. A novel K156E substitution in ALAS2 was discovered in 1 pyridoxine-responsive patient. The functional study showed that this substitution severely decreases ALAS2 enzyme activity. In 1 pyridoxine-refractory patient, no mutations were detected in ALAS2, SLC25A38 or GLRX5. CONCLUSION: Our report extends the list of known ALAS2 mutations, with the addition of a novel K156E substitution that is responsive to pyridoxine treatment and contributes to the general knowledge of congenital SA cases characterized worldwide.
- 650 _2
- $a 5-aminolevulátsynthetasa $x genetika $x metabolismus $7 D000624
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a sideroblastická anemie $x farmakoterapie $x enzymologie $x genetika $7 D000756
- 650 _2
- $a sekvence nukleotidů $7 D001483
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a pyridoxin $x terapeutické užití $7 D011736
- 650 _2
- $a sekvenční seřazení $7 D016415
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Horvathova, Monika
- 700 1_
- $a Mojzikova, Renata
- 700 1_
- $a Belohlavkova, Petra
- 700 1_
- $a Cermak, Jaroslav
- 700 1_
- $a Divoky, Vladimir
- 773 0_
- $w MED00000045 $t Acta haematologica $x 1421-9662 $g Roč. 125, č. 4 (20110120), s. 193-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21252495 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20141211095741 $b ABA008
- 999 __
- $a ok $b bmc $g 949905 $s 785209
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 125 $c 4 $d 193-7 $e 20110120 $i 1421-9662 $m Acta haematologica $n Acta Haematol $x MED00000045
- GRA __
- $a NS10281 $p MZ0
- LZP __
- $a Pubmed-20120817/11/03